NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free PGEN Stock Alerts $1.40 -0.04 (-2.78%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$1.39▼$1.4950-Day Range$1.27▼$1.7552-Week Range$0.84▼$1.88Volume761,242 shsAverage Volume745,017 shsMarket Capitalization$353.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Precigen alerts: Email Address Precigen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside542.9% Upside$9.00 Price TargetShort InterestBearish11.81% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.03Based on 23 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector165th out of 929 stocksPharmaceutical Preparations Industry63rd out of 433 stocks 4.3 Analyst's Opinion Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePrecigen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Precigen's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.81% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 4.70%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Precigen is -0.77. Previous Next 2.2 News and Social Media Coverage News SentimentPrecigen has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Precigen this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Precigen to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.33) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Precigen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Precigen Stock (NASDAQ:PGEN)Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More PGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGEN Stock News HeadlinesMay 17 at 5:48 AM | americanbankingnews.comPrecigen, Inc. to Post FY2028 Earnings of $0.62 Per Share, HC Wainwright Forecasts (NASDAQ:PGEN)May 17 at 4:40 AM | americanbankingnews.comPrecigen (NASDAQ:PGEN) Rating Reiterated by Stifel NicolausMay 15 at 11:52 PM | markets.businessinsider.comBuy Rating Affirmed for Precigen Amid Promising Clinical Data and Strong Financial OutlookMay 15 at 6:33 AM | finanznachrichten.dePrecigen, Inc.: Precigen Reports First Quarter 2024 Financial Results and Business UpdatesMay 15 at 6:33 AM | markets.businessinsider.comBuy Rating Affirmed for Precigen Amid Promising Clinical Developments and Strategic FDA AlignmentMay 14 at 9:04 PM | investorplace.comPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q1 2024May 14 at 4:05 PM | prnewswire.comPrecigen Reports First Quarter 2024 Financial Results and Business UpdatesMay 14 at 3:33 PM | markets.businessinsider.comHere's what to expect from Precigen's earnings reportMay 14 at 10:42 AM | msn.comStocks Mixed as US PPI Report Signals Sticky Price PressuresMay 14 at 6:40 AM | theglobeandmail.comStock Index Futures Tread Water Ahead of Key U.S. PPI Data and Powell RemarksMay 13, 2024 | msn.comPrecigen Q1 2024 Earnings PreviewMay 12, 2024 | americanbankingnews.comPrecigen (PGEN) to Release Quarterly Earnings on TuesdayMay 8, 2024 | prnewswire.comPrecigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingApril 26, 2024 | finanznachrichten.deActym Therapeutics Inc.: Actym Therapeutics Appoints Thomas Smart as CEOApril 24, 2024 | prnewswire.comPrecigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingApril 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOMarch 28, 2024 | prnewswire.comPrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)March 22, 2024 | msn.comJ.P. Morgan cuts Precigen to underweight, cites burn rateMarch 21, 2024 | bizjournals.comGermantown biotech expands manufacturing capacity, headcount ahead of potential product launchMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial StabilityMarch 20, 2024 | finance.yahoo.comPrecigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)March 19, 2024 | seekingalpha.comPrecigen, Inc. (PGEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | investorplace.comPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023See More Headlines Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/16/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees202Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$14.00 Low Stock Price Target$6.00 Potential Upside/Downside+542.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,900,000.00 Net Margins-1,540.63% Pretax Margin-1,547.98% Return on Equity-55.47% Return on Assets-43.25% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$6.22 million Price / Sales56.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book2.92Miscellaneous Outstanding Shares248,920,000Free Float145,120,000Market Cap$348.49 million OptionableOptionable Beta1.77 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Randal J. Kirk J.D. (Age 71)Executive Chairman Comp: $100kDr. Helen Sabzevari MPH (Age 61)Ph.D., President, CEO & Director Comp: $1.29MMr. Harry Thomasian Jr. (Age 61)Chief Financial Officer Comp: $524.04kMr. Rutul R. Shah (Age 43)Chief Operating Officer Comp: $393.54kMr. Donald P. Lehr (Age 49)Chief Legal Officer & Corporate Secretary Comp: $652.4kMr. Jeffrey Thomas Perez (Age 52)Senior Vice President of Intellectual Property Affairs Comp: $570.24kMr. Steven HarasymVP & Head of Investor RelationsMr. Rob RussellVP & Head of Human ResourcesDr. Douglas E. Brough Ph.D. (Age 69)Senior VP & Head of Research Dr. Bryan T. Butman Ph.D. (Age 71)Senior VP & Head of CMC More ExecutivesKey CompetitorsNanobiotixNASDAQ:NBTXAtea PharmaceuticalsNASDAQ:AVIRVerastemNASDAQ:VSTMADC TherapeuticsNYSE:ADCTAC ImmuneNASDAQ:ACIUView All CompetitorsInsiders & InstitutionsEntryPoint Capital LLCBought 21,479 shares on 5/14/2024Ownership: 0.009%Vanguard Group Inc.Bought 19,875 shares on 5/10/2024Ownership: 2.719%Fore Capital LLCSold 50,000 shares on 5/7/2024Ownership: 0.123%SG Americas Securities LLCSold 24,583 shares on 5/7/2024Ownership: 0.021%Iridian Asset Management LLC CTBought 86,340 shares on 5/2/2024Ownership: 0.840%View All Insider TransactionsView All Institutional Transactions PGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Precigen stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares. View PGEN analyst ratings or view top-rated stocks. What is Precigen's stock price target for 2024? 5 analysts have issued 1 year target prices for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 542.9% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts. How have PGEN shares performed in 2024? Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has increased by 4.5% and is now trading at $1.40. View the best growth stocks for 2024 here. When is Precigen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PGEN earnings forecast. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) issued its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.54 million. Precigen had a negative trailing twelve-month return on equity of 65.36% and a negative net margin of 1,781.72%. During the same period in the prior year, the firm earned ($0.10) earnings per share. What ETFs hold Precigen's stock? ETFs with the largest weight of Precigen (NASDAQ:PGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC). Who are Precigen's major shareholders? Precigen's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.72%), Iridian Asset Management LLC CT (0.84%), Sanders Morris Harris LLC (0.28%), Fore Capital LLC (0.12%), LexAurum Advisors LLC (0.04%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, John N Digiacomo, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PGEN) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
